gbs
Reading File
Finding Sources
Searching PubMed
"Guillain-Barre syndrome" treatment
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
I now have comprehensive information from multiple authoritative textbooks. Let me compile a thorough overview of GBS.
Guillain-Barré Syndrome (GBS)
Definition & Background
GBS is an acute immune-mediated polyradiculoneuropathy — the leading cause of acute flaccid paralysis in Western countries since the eradication of polio. First described by Guillain, Barré, and Strohl in 1916, it is characterized by progressive weakness, areflexia, paresthesias, and albuminocytological dissociation in the CSF.
- Incidence: ~1.8 per 100,000/year; increases with age
- Males > females (1.5:1)
- Mortality: ~1–5% (down from 33% before positive-pressure ventilation)
Pathophysiology
Approximately two-thirds of cases are triggered by a preceding infection 1–4 weeks before onset. Microbe-specific T cells and antibodies are generated that cross-react with peripheral nerve antigens (molecular mimicry). Both T-cell–mediated and antibody-mediated mechanisms contribute, though T-cell responses are believed dominant.
Key triggers:
- Campylobacter jejuni (most common bacterial trigger)
- Epstein-Barr virus, cytomegalovirus, HIV
- Zika virus, SARS-CoV-2
- Vaccines (rare association)
Injury is most extensive in nerve roots and proximal nerve segments, with mononuclear cell infiltrates rich in macrophages causing demyelination or axonal damage.
Subtypes
| Subtype | Key Features |
|---|---|
| AIDP (Acute Inflammatory Demyelinating Polyradiculoneuropathy) | Most common in Europe/North America; demyelinating |
| AMAN (Acute Motor Axonal Neuropathy) | Pure motor; summer epidemics in northern China; C. jejuni-associated |
| AMSAN (Acute Motor-Sensory Axonal Neuropathy) | Severe; poor recovery; both motor and sensory axons |
| Miller-Fisher Syndrome (MFS) | Ophthalmoplegia, ataxia, areflexia; anti-GQ1b antibodies; 6% of GBS in West, 18% in Taiwan |
| Pharyngeal-cervical-brachial variant | Dysphagia, facial/arm weakness |
| Facial diplegia with paresthesias | — |
| Paraparetic variant | — |
Clinical Features
Required for diagnosis:
- Progressive weakness of both arms and legs
- Areflexia or hyporeflexia
Classic presentation:
- Ascending weakness starting in the legs, progressing over hours to days
- Severity ranges from mild (able to walk) to near-total quadriplegia
- Cranial nerve involvement in 45–75% — bilateral facial paresis most common
- Respiratory failure in 9–30% → requires mechanical ventilation
- Sensory loss is mild/distal; vibration sense affected most
- Pain (extremities, back, interscapular) in ~70% during acute phase
Autonomic dysfunction (~65% of hospitalized patients):
- Orthostatic hypotension, urinary retention, GI atony
- Sinus tachycardia, tachyarrhythmias, bradycardia, heart block, asystole ("vagal spells" — may be triggered by tracheal suctioning)
- ECG changes: T-wave abnormalities, ST depression, QT prolongation, heart block
Diagnosis
Clinical criteria (Brighton/Asbury-Cornblath):
| Category | Finding |
|---|---|
| Required | Progressive bilateral limb weakness + areflexia/hyporeflexia |
| CSF | ↑ Protein with <10 cells/μL (albuminocytological dissociation) |
| EMG/NCS | Nerve conduction slowing or conduction block (demyelination) or reduced CMAP amplitudes (axonal) |
- CSF protein often normal in the first week — repeat if initial LP normal
- Anti-GQ1b antibodies positive in ~90% of Miller-Fisher syndrome
Treatment
| Treatment | Mechanism | Notes |
|---|---|---|
| IV Immunoglobulin (IVIG) | Suppresses immune response (multiple mechanisms) | 0.4 g/kg/day × 5 days; equivalent efficacy to PE |
| Plasmapheresis (PE) | Removes offending antibodies/complement | 4–6 exchanges over 2 weeks; most benefit if started within 2 weeks of onset |
| Supportive care | — | Mechanical ventilation, DVT prophylaxis, pain management, rehabilitation |
⚠️ Corticosteroids are NOT effective in GBS and are not recommended.
IVIG + PE combined is no better than either alone.
Respiratory monitoring (EGRIS score): Patients at highest risk for intubation (EGRIS 5–7) should be admitted to the ICU. The 20-30-40 rule is commonly used: intubate if FVC <20 mL/kg, MIP <30 cmH₂O, or MEP <40 cmH₂O.
Prognosis
- Progression typically plateaus by 4 weeks in the vast majority
- Recovery begins 2–4 weeks after progression ceases
- Most patients recover with time; ~20% remain unable to walk independently at 6 months
- Poor prognosis factors: older age, rapid progression, severe weakness, preceding C. jejuni infection, axonal subtype (AMSAN)
Chronic Counterpart: CIDP
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) follows a similar immune mechanism but progresses for ≥2 months or follows a relapsing-remitting course. Unlike GBS, CIDP responds to corticosteroids, IVIG, and plasmapheresis long-term.
Sources: Bradley and Daroff's Neurology in Clinical Practice; Robbins & Kumar Basic Pathology; Fishman's Pulmonary Diseases and Disorders; Miller's Anesthesia
This is a shared conversation. Sign in to Orris to start your own chat.